LAVAL, Quebec / Jun 06, 2024 / Business Wire / Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 5, 2024. The detailed results of the votes received by proxy are as follows:
Election of Directors
Director Nominees |
|
| ||
|
|
|
| |
Daniel N. Chicoine | 6,490,732 | 109,026 | 98.3% | 1.7% |
Anthony E. Dobranowski | 6,508,888 | 90,870 | 98.6% | 1.4% |
John C. London | 6,533,190 | 66,568 | 99.0% | 1.0% |
Deborah Shannon-Trudeau | 6,541,297 | 58,461 | 99.1% | 0.9% |
Serge Verreault | 6,590,211 | 9,547 | 99.9% | 0.1% |
Reappointment of External Auditors
Outcome |
|
| ||
|
|
|
| |
Ernst & Young LLP reappointed | 7,212,551 | 148,556 | 98.0% | 2.0% |
Approval of the Continuation of Crescita’s Share Incentive Plan
Outcome |
|
| ||
|
|
|
| |
Share Incentive Plan approved | 6,526,477 | 73,281 | 98.9% | 1.1% |
About Crescita Therapeutics Inc.
Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and a commercial stage prescription product. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For more information visit, www.crescitatherapeutics.com.
| Last Trade: | C$0.56 |
| Daily Volume: | 0 |
| Market Cap: | C$10.710M |
March 18, 2025 November 06, 2024 August 07, 2024 July 22, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
